Publications

Authors:

Santi, Roberto Mario; Ceccarelli, Manuela; Bernocco, Elisa; Monagheddu, Chiara; Evangelista, Andrea; Valeri, Federica; Monaco, Federico; Vitolo, Umberto; Cortelazzo, Sergio; Cabras, Maria Giuseppina; Spina, Michele; Baldini, Luca; Boccomini, Carola; Chiappella, Annalisa; DI BARI, Alessia; Luminari, Stefano; Visco, Carlo; Calabrese, Marco; Limberti, Giulia; Levis, Alessandro; Contino, Laura; Ciccone, Giovannino; Ladetto, Marco

Title:

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)

Year:

2017

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Thrombosis and Haemostasis

ISSN of journal:

0340-6245

N° Volume:

117

Number or Folder:

08

Page numbers:

1615-1621

Keyword:

Khorana Score; Venous thromboembolism; non-Hodgkin lymphoma

Short description of contents:

Current data suggests that the risk of venous thromboembolism (VTE) in patients with non-Hodgkin lymphoma (NHL) is comparable to that observed in patients with solid tumours, although more robust confirmatory analyses are required. With that in mind, we investigated the occurrence of VTE in a pooled analysis of 12 "Fondazione Italiana Linfomi" (FIL) prospective clinical studies. Specifically, we wished to assess the cumulative incidence of VTE in NHL patients, evaluate the predictive value of the Khorana Score (KS), and identify other potential risk factors for VTEs. Data for VTE occurrence were retrieved from study databases and pharmacovigilance reports. Our analysis includes 1717 patients from 12 prospective phase II and III trials, including newly diagnosed NHL. We observed 53 VTEs (any grade) in 46 patients, with 20 severe VTEs in 17 patients. The cumulative incidences for "all-grade" or grade ≥3 VTEs were 2.9 % (95 % CI: 2.1-3.8) and 1.1 % (95 % CI: 0.6-1.6), respectively. KS categories were positively associated with the risk of VTE of any grade, and with severe events (i. e. grade ≥3; Gray's test p-values = 0.048 and 0.012, respectively). Among NHL patients, those with diffuse large B-cell lymphoma (DLBCL) showed a greater risk of (any grade) VTE (HR: 3.42, 95 % CI: 1.32-8.84, p-value = 0.011). Our study indicates that 1) VTE is a relevant complication for NHL patients, 2) KS is predictive of VTE events and 3) DLBCL histotype is an independent risk factor for VTE incidence, for which preventative interventions could be considered.

Product ID:

107979

Handle IRIS:

11562/993672

Last Modified:

November 15, 2022

Bibliographic citation:

Santi, Roberto Mario; Ceccarelli, Manuela; Bernocco, Elisa; Monagheddu, Chiara; Evangelista, Andrea; Valeri, Federica; Monaco, Federico; Vitolo, Umberto; Cortelazzo, Sergio; Cabras, Maria Giuseppina; Spina, Michele; Baldini, Luca; Boccomini, Carola; Chiappella, Annalisa; DI BARI, Alessia; Luminari, Stefano; Visco, Carlo; Calabrese, Marco; Limberti, Giulia; Levis, Alessandro; Contino, Laura; Ciccone, Giovannino; Ladetto, Marco, Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL) «Thrombosis and Haemostasis» , vol. 117 , n. 08 , 2017 , pp. 1615-1621

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo